Optimal serum ferritin levels for iron deficiency anemia during oral iron therapy (OIT) in Japanese hemodialysis patients with minor inflammation and benefit of intravenous iron therapy for OIT-nonresponders

Nutrients

Volumn 10, Issue 4, 2018, Pages

  Takasawa, Kazuya ^a   Takaeda, Chikako ^a   Wada, Takashi ^b   Ueda, Norishi ^a  

^a Public Central Hospital of Matto Ishikawa   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Ferritin; Hemodialysis; Hepcidin 25; Inflammation; Iron deficiency anemia; Oral iron therapy

Indexed keywords

ANTIANEMIC AGENT; FERRIC ION; FERRITIN; FERROUS FUMARATE; FERROUS ION; IRON; IRON SACCHARATE; SACCHARIC ACID; TRACE ELEMENT;

ADULT; AGED; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; FEMALE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AGED; ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; FERRITINS; FERROUS COMPOUNDS; GLUCARIC ACID; HEMATINICS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TRACE ELEMENTS;

EID: 85044771871     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu10040428     Document Type: Article

References (64)

1. Vaziri, N.D. Safety issues in iron treatment in CKD. Semin. Nephrol. 2016, 36, 112–118. [CrossRef] [PubMed]
2. Lopez, A.; Cacoub, P.; Macdougall, I.C.; Peyrin-Biroulet, L. Iron deficiency anaemia. Lancet 2016, 387, 907–916. [CrossRef]
3. The Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2012, 2, 279–335.
4. Macdougall, I.C.; Bock, A.H.; Carrera, F.; Eckardt, K.U.; Gaillard, C.; Van Wyck, D.; Roubert, B.; Nolen, J.G.; Roger, S.D.; FIND-CKD Study Investigators. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol. Dial. Transplant. 2014, 29, 2075–2084. [CrossRef] [PubMed]
5. Tsubakihara, Y.; Nishi, S.; Akiba, T.; Hirakata, H.; Iseki, K.; Kubota, M.; Kuriyama, S.; Komatsu, Y.; Suzuki, M.; Nakai, S.; et al. 2008 Japanese Society for Dialysis Therapy: Guidelines for renal anemia in chronic kidney disease. Ther. Apher. Dial. 2010, 14, 240–275. [CrossRef] [PubMed]
6. Bazeley, J.; Bieber, B.; Li, Y.; Morgenstern, H.; de Sequera, P.; Combe, C.; Yamamoto, H.; Gallagher, M.; Port, F.K.; Robinson, B.M. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2011, 6, 2452–2461. [CrossRef] [PubMed]
7. Kawaguchi, T.; Tong, L.; Robinson, B.M.; Sen, A.; Fukuhara, S.; Kurokawa, K.; Canaud, B.; Lameire, N.; Port, F.K.; Pisoni, R.L. C-reactive protein and mortality in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron Clin. Pract. 2011, 117, c167–c178. [CrossRef] [PubMed]
8. Albaramki, J.; Hodson, E.M.; Craig, J.C.; Webster, A.C. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst. Rev. 2012, 18, CD007857. [CrossRef] [PubMed]
9. Rostoker, G.; Griuncelli, M.; Loridon, C.; Magna, T.; Janklewicz, P.; Drahi, G.; Dahan, H.; Cohen, Y. Maximal standard dose of parenteral iron for hemodialysis patients: An MRI-based decision tree learning analysis. PLoS ONE 2014, 9, e115096. [CrossRef] [PubMed]
10. Rostoker, G.; Griuncelli, M.; Loridon, C.; Magna, T.; Machado, G.; Drahi, G.; Dahan, H.; Janklewicz, P.; Cohen, Y. Reassessment of iron biomarkers for prediction of dialysis iron overload: An MRI study. PLoS ONE 2015, 10, e0132006. [CrossRef] [PubMed]
11. Bailie, G.R.; Larkina, M.; Goodkin, D.A.; Li, Y.; Pisoni, R.L.; Bieber, B.; Mason, N.; Tong, L.; Locatelli, F.; Marshall, M.R.; et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015, 87, 162–168. [CrossRef] [PubMed]
12. Kuo, K.L.; Hung, S.C.; Lin, Y.P.; Tang, C.F.; Lee, T.S.; Lin, C.P.; Tarng, D.C. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS ONE 2012, 7, e50295. [CrossRef] [PubMed]
13. Luo, J.; Jensen, D.E.; Maroni, B.J.; Brunelli, S.M. Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients. Am. J. Kidney Dis. 2016, 68, 763–771. [CrossRef] [PubMed]
14. Ogawa, C.; Tsuchiya, K.; Kanda, F.; Maeda, T. Low levels of serum ferritin lead to adequate hemoglobin levels and good survival in hemodialysis patients. Am. J. Nephrol. 2014, 40, 561–570. [CrossRef] [PubMed]
15. Del Vecchio, L.; Longhi, S.; Locatelli, F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin. Kidney J. 2016, 9, 260–267. [CrossRef] [PubMed]
16. Nakanishi, T.; Kuragano, T.; Nanami, M.; Otaki, Y.; Nonoguchi, H.; Hasuike, Y. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am. J. Nephrol. 2010, 32, 439–446. [CrossRef] [PubMed]
17. Łukaszyk, E.; Łukaszyk, M.; Koc-Żórawska, E.; Tobolczyk, J.; Bodzenta-Łukaszyk, A.; Małyszko, J. Iron status and inflammation in early stages of chronic kidney disease. Kidney Blood Press. Res. 2015, 40, 366–373. [CrossRef] [PubMed]
18. Kopelman, R.C.; Smith, L.; Peoples, L.; Biesecker, R.; Rizkala, A.R. Functional iron deficiency in hemodialysis patients with high ferritin. Hemodial. Int. 2007, 11, 238–246. [CrossRef] [PubMed]
19. Jenq, C.C.; Tian, Y.C.; Wu, H.H.; Hsu, P.Y.; Huang, J.Y.; Chen, Y.C.; Fang, J.T.; Yang, C.W. Effectiveness of oral and intravenous iron therapy in haemodialysis patients. Int. J. Clin. Pract. 2008, 62, 416–422. [CrossRef] [PubMed]
20. Kalra, P.A.; Bhandari, S.; Saxena, S.; Agarwal, D.; Wirtz, G.; Kletzmayr, J.; Thomsen, L.L.; Coyne, D.W. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol. Dial. Transplant. 2016, 31, 646–655. [CrossRef] [PubMed]
21. Agarwal, R.; Kusek, J.W.; Pappas, M.K. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015, 88, 905–914. [CrossRef] [PubMed]
22. Fishbane, S.; Mathew, A.; Vaziri, N.D. Iron toxicity: Relevance for dialysis patients. Nephrol. Dial. Transplant. 2014, 29, 255–259. [CrossRef] [PubMed]
23. Lenga, I.; Lok, C.; Marticorena, R.; Hunter, J.; Dacouris, N.; Goldstein, M. Role of oral iron in the management of long-term hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2007, 2, 688–693. [CrossRef] [PubMed]
24. Tsuchida, A.; Paudyal, B.; Paudyal, P.; Ishii, Y.; Hiromura, K.; Nojima, Y.; Komai, M. Effectiveness of oral iron to manage anemia in long-term hemodialysis patients with the use of ultrapure dialysate. Exp. Ther. Med. 2010, 1, 777–781. [CrossRef] [PubMed]
25. Takasawa, K.; Takaeda, C.; Maeda, T.; Ueda, N. Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients. Nutrients 2015, 7, 103–118. [CrossRef] [PubMed]
26. Sanai, T.; Ono, T.; Fukumitsu, T. Beneficial effects of oral iron in Japanese patients on hemodialysis. Intern. Med. 2017, 56, 2395–2399. [CrossRef] [PubMed]
27. Kalantar-Zadeh, K.; Regidor, D.L.; McAllister, C.J.; Michael, B.; Warnock, D.G. Time-dependent associations between iron and mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2005, 16, 3070–3080. [CrossRef] [PubMed]
28. Kovesdy, C.P.; Estrada, W.; Ahmadzadeh, S.; Kalantar-Zadeh, K. Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4, 435–441. [CrossRef] [PubMed]
29. Ramanathan, G.; Olynyk, J.K.; Ferrari, P. Diagnosing and preventing iron overload. Hemodial. Int. 2017, 21 (Suppl. 1), S58–S67. [CrossRef] [PubMed]
30. Chauveau, P.; Level, C.; Lasseur, C.; Bonarek, H.; Peuchant, E.; Montaudon, D.; Vendrely, B.; Combe, C. C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: A 2-year prospective study. J. Ren. Nutr. 2003, 13, 137–143. [CrossRef] [PubMed]
31. Jenq, C.C.; Hsu, C.W.; Huang, W.H.; Chen, K.H.; Lin, J.L.; Lin-Tan, D.T. Serum ferritin levels predict all-cause and infection-cause 1-year mortality in diabetic patients on maintenance hemodialysis. Am. J. Med. Sci. 2009, 337, 188–194. [CrossRef] [PubMed]
32. Hasuike, Y.; Nonoguchi, H.; Tokuyama, M.; Ohue, M.; Nagai, T.; Yahiro, M.; Nanami, M.; Otaki, Y.; Nakanishi, T. Serum ferritin predicts prognosis in hemodialysis patients: The Nishinomiya study. Clin. Exp. Nephrol. 2010, 14, 349–355. [CrossRef] [PubMed]
33. Maruyama, Y.; Yokoyama, K.; Yokoo, T.; Shigematsu, T.; Iseki, K.; Tsubakihara, Y. The different association between serum ferritin and mortality in hemodialysis and peritoneal dialysis patients using Japanese nationwide dialysis registry. PLoS ONE 2015, 10, e0143430. [CrossRef] [PubMed]
34. Kim, T.; Streja, E.; Soohoo, M.; Rhee, C.M.; Eriguchi, R.; Kim, T.W.; Chang, T.I.; Obi, Y.; Kovesdy, C.P.; Kalantar-Zadeh, K. Serum ferritin variations and mortality in incident hemodialysis patients. Am. J. Nephrol. 2017, 46, 120–130. [CrossRef] [PubMed]
35. Floege, J.; Gillespie, I.A.; Kronenberg, F.; Anker, S.D.; Gioni, I.; Richards, S.; Pisoni, R.L.; Robinson, B.M.; Marcelli, D.; Froissart, M.; et al. Development and validation of a predictive mortality risk score from a European hemodialysis cohort. Kidney Int. 2015, 87, 996–1008. [CrossRef] [PubMed]
36. Shoji, T.; Niihata, K.; Fukuma, S.; Fukuhara, S.; Akizawa, T.; Inaba, M. Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflammation. Clin. Exp. Nephrol. 2017, 21, 685–693. [CrossRef] [PubMed]
37. Musanovic, A.; Trnacevic, S.; Mekic, M.; Musanovic, A. The influence of inflammatory markers and CRP predictive value in relation to the target hemoglobin level in patients on chronic hemodialysis. Med. Arch. 2013, 67, 361–364. [CrossRef] [PubMed]
38. Miskulin, D.C.; Tangri, N.; Bandeen-Roche, K.; Zhou, J.; McDermott, A.; Meyer, K.B.; Ephraim, P.L.; Michels, W.M.; Jaar, B.G.; Crews, D.C.; et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 2014, 9, 1930–1939. [CrossRef] [PubMed]
39. Ueda, N.; Takasawa, K. Role of hepcidin-25 in chronic kidney disease: Anemia and beyond. Curr. Med. Chem. 2017, 24, 1417–1452. [CrossRef] [PubMed]
40. McMahon, L.P.; Kent, A.B.; Kerr, P.G.; Healy, H.; Irish, A.B.; Cooper, B.; Kark, A.; Roger, S.D. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: A randomized controlled trial. Nephrol. Dial. Transplant. 2010, 25, 920–926. [CrossRef] [PubMed]
41. El-Khatib, M.; Duncan, H.J.; Kant, K.S. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients. Nephrology 2006, 11, 400–404. [CrossRef] [PubMed]
42. Chand, S.; Ward, D.G.; Ng, Z.Y.; Hodson, J.; Kirby, H.; Steele, P.; Rooplal, I.; Bantugon, F.; Iqbal, T.; Tselepis, C.; et al. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. J. Nephrol. 2015, 28, 81–88. [CrossRef] [PubMed]
43. Tovbin, D.; Schnaider, A.; Vorobiov, M.; Rogachev, B.; Basok, A.; Shull, P.; Novack, V.; Friger, M.; Avramov, D.; Zlotnik, M. Minor impairment of oral iron absorption in non-diabetic new dialysis patients. J. Nephrol. 2005, 18, 174–180. [PubMed]
44. Kooistra, M.P.; Niemantsverdriet, E.C.; van Es, A.; Mol-Beermann, N.M.; Struyvenberg, A.; Marx, J.J. Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium. Nephrol. Dial. Transplant. 1998, 13, 82–88. [CrossRef] [PubMed]
45. Sarafidis, P.A.; Rumjon, A.; MacLaughlin, H.L.; Macdougall, I.C. Obesity and iron deficiency in chronic kidney disease: The putative role of hepcidin. Nephrol. Dial. Transplant. 2012, 27, 50–57. [CrossRef] [PubMed]
46. Aydin, Z.; Gursu, M.; Karadag, S.; Uzun, S.; Sumnu, A.; Doventas, Y.; Ozturk, S.; Kazancioglu, R. The relationship of prohepcidin levels with anemia and inflammatory markers in non-diabetic uremic patients: A controlled study. Ren. Fail. 2014, 36, 1253–1257. [CrossRef] [PubMed]
47. Malyszko, J.; Malyszko, J.S.; Pawlak, K.; Mysliwiec, M. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. Am. J. Hematol. 2006, 81, 832–837. [CrossRef] [PubMed]
48. Samouilidou, E.; Pantelias, K.; Petras, D.; Tsirpanlis, G.; Bakirtzi, J.; Chatzivasileiou, G.; Tzanatos, H.; Grapsa, E. Serum hepcidin levels are associated with serum triglycerides and interleukin-6 concentrations in patients with end-stage renal disease. Ther Apher Dial. 2014, 18, 279–283. [CrossRef] [PubMed]
49. Mercadal, L.; Metzger, M.; Haymann, J.P.; Thervet, E.; Boffa, J.J.; Flamant, M.; Vrtovsnik, F.; Gauci, C.; Froissart, M.; Stengel, B.; et al. A 3-marker index improves the identification of iron disorders in CKD anaemia. PLoS ONE 2014, 9, e84144. [CrossRef] [PubMed]
50. Tutal, E.; Sezer, S.; Bilgic, A.; Aldemir, D.; Turkoglu, S.; Demirel, O.; Ozdemir, N.; Haberal, M. Influence of oxidative stress and inflammation on rHuEPO requirements of hemodialysis patients with CRP values “in normal range”. Transplant. Proc. 2007, 39, 3035–3040. [CrossRef] [PubMed]
51. Shinzato, T.; Abe, K.; Furusu, A.; Harada, T.; Shinzato, K.; Miyazaki, M.; Kohno, S. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. Med. Sci. Monit. 2008, 14, CR431–CR437. [PubMed]
52. Prats, M.; Font, R.; García, C.; Muñoz-Cortés, M.; Cabré, C.; Jariod, M.; Romeu, M.; Giralt, M.; Martinez-Vea, A. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients. Clin. Nephrol. 2014, 81, 419–426. [CrossRef] [PubMed]
53. Sakellariou, G. Do serum and red blood cell folate levels indicate iron response in hemodialysis patients? ASAIO J. 2006, 52, 163–168.
54. Besarab, A.; Chernyavskaya, E.; Motylev, I.; Shutov, E.; Kumbar, L.M.; Gurevich, K.; Chan, D.T.; Leong, R.; Poole, L.; Zhong, M.; et al. Roxadustat (FG-4592): Correction of anemia in incident dialysis patients. J. Am. Soc. Nephrol. 2016, 27, 1225–1233. [CrossRef] [PubMed]
55. Movafagh, S.; Raj, D.; Sanaei-Ardekani, M.; Bhatia, D.; Vo, K.; Mahmoudieh, M.; Rahman, R.; Kim, E.H.; Harralson, A.F. Hypoxia inducible factor 1: A urinary biomarker of kidney disease. Clin. Transl. Sci. 2017, 10, 201–207. [CrossRef] [PubMed]
56. Kapoian, T.; O’Mara, N.B.; Carreon, M.; Gajary, A.; Rizkala, A.; Lefavour, G.; Sherman, R.A.; Walker, J. Iron indices and intravenous ferumoxytol: Time to steady-state. Ann. Pharmacother. 2012, 46, 1308–1314. [CrossRef] [PubMed]
57. Pisani, A.; Riccio, E.; Sabbatini, M.; Andreucci, M.; Del Rio, A.; Visciano, B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial. Nephrol. Dial. Transplant. 2015, 30, 645–652. [CrossRef] [PubMed]
58. Lewis, J.B.; Sika, M.; Koury, M.J.; Chuang, P.; Schulman, G.; Smith, M.T.; Whittier, F.C.; Linfert, D.R.; Galphin, C.M.; Athreya, B.P.; et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J. Am. Soc. Nephrol. 2015, 26, 493–503. [CrossRef] [PubMed]
59. Deira, J.; Martín, M.; Sánchez, S.; Garrido, J.; Núñez, J.; Tabernero, J.M. Evaluation of intestinal iron absorption by indirect methods in patients on hemodialysis receiving oral iron and recombinant human. Am. J. Kidney Dis. 2002, 39, 594–599. [CrossRef]
60. Killip, S.; Bennett, J.M.; Chambers, M.D. Iron deficiency anemia. Am. Fam. Physician 2007, 75, 671–678. [PubMed]
61. Zariwala, M.G.; Somavarapu, S.; Farnaud, S.; Renshaw, D. Comparison study of oral iron preparations using a human intestinal model. Sci. Pharm. 2013, 81, 1123–1139. [CrossRef] [PubMed]
62. Kiss, J.E.; Brambilla, D.; Glynn, S.A.; Mast, A.E.; Spencer, B.R.; Stone, M.; Kleinman, S.H.; Cable, R.G.; National Heart, Lung, and Blood Institute (NHLBI) Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Oral iron supplementation after blood donation: A randomized clinical trial. JAMA 2015, 313, 575–583. [CrossRef] [PubMed]
63. Al-Hawas, F.; Abdalla, A.H.; Popovich, W.; Mousa, D.H.; Al-Sulaiman, M.H.; Al-Khader, A.A. Use of i.v. iron saccharate in haemodialysis patients not responding to oral iron and erythropoietin. Nephrol. Dial. Transplant. 1997, 12, 2801–2802. [CrossRef] [PubMed]
64. Canavese, C.; Bergamo, D.; Ciccone, G.; Burdese, M.; Maddalena, E.; Barbieri, S.; Thea, A.; Fop, F. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Nephrol. Dial. Transplant. 2004, 19, 1564–1570. [CrossRef] [PubMed]